Heritable Disorders of Connective Tissue¶
Chapter 425 | Part 12: Endocrinology
KEY CLINICAL POINTS¶
- Osteogenesis Imperfecta (OI) is a genetically heterogeneous disorder characterized by bone fragility, fractures, and variable skeletal deformities due to collagen defects.
- Ehlers-Danlos Syndromes (EDS) are a group of connective tissue disorders marked by joint hypermobility, skin hyperextensibility, and tissue fragility, with over 13 distinct types.
- Chondrodysplasias (CDs) are skeletal dysplasias caused by mutations in collagen or proteoglycan genes, leading to disproportionate short stature and joint abnormalities.
- Heritable thoracic aortic aneurysm disease (HTAD) includes syndromic forms like Marfan syndrome (MFS) and Loeys-Dietz syndrome (LDS), often linked to TGF- β signaling defects.
- Genetic testing and multidisciplinary management are critical for diagnosing and treating these disorders, with targeted therapies like bisphosphonates, denosumab, and vosoritide showing promise.
1. DEFINITION & OVERVIEW¶
Heritable disorders of connective tissue encompass a wide range of genetic conditions affecting collagen, proteoglycans, and other extracellular matrix components. These disorders manifest clinically with skeletal abnormalities, joint hypermobility, skin fragility, and vascular complications. Key examples include Osteogenesis Imperfecta (OI), Ehlers-Danlos Syndromes (EDS), Chondrodysplasias (CDs), and Heritable Thoracic Aortic Aneurysm Disease (HTAD).
Table 425-1: Constituents of Connective Tissues and Their Associated Heritable Conditions¶
| PROTEIN | TISSUE DISTRIBUTION | DISEASE | KEY MANIFESTATIONS |
|---|---|---|---|
| Collagen I | Bone, cornea, dermis, tendon | Osteogenesis Imperfecta | Bone fragility with fractures and deformity; blue sclerae; dentinogenesis imperfecta; hearing loss |
| Collagen III | Dermis, aorta, uterus, intestine | Vascular EDS | Arterial, intestinal, and uterine fragility; thin translucent skin; easy bruising |
| Collagen V | Placental tissue, bone, dermis, cornea | Classic EDS | Joint hypermobility; skin hyperextensibility; atrophic scarring |
| Collagen VII | Skin, amniotic membrane, mucosal epithelium | Dystrophic epidermolysis bullosa | Skin blistering; oral and esophageal blistering; corneal erosions |
| PROTEIN | TISSUE DISTRIBUTION | DISEASE | KEY MANIFESTATIONS |
|---|---|---|---|
| Collagen IX | Cartilage, vitreous | Stickler syndrome | Spondyloepiphyseal dysplasia; early-onset osteoarthritis; high myopia; vitreoretinal abnormalities; hearing loss; cleft palate; midfacial hypoplasia |
| Collagen XI | Cartilage, intervertebral disk | Various chondrodysplasias | Skeletal dysplasia; ocular manifestations; hearing loss; orofacial findings |
| Fibrillin 1 | Dermis, arterial wall, lung | Marfan syndrome | Aortic root aneurysm or dissection; ectopia lentis; marfanoid habitus |
| Elastin | Dermis, arterial wall, lung | Cutis laxa | Wrinkled, redundant, sagging inelastic skin |
| Fibrillin 2 | Bruch membrane | Congenital contractural arachnodactyly (CCA) | Tall stature; arachnodactyly; (kypho)scoliosis; pectus deformities; contractures; muscle hypoplasia; mild cardiovascular involvement; long, narrow face, highly arched palate, micrognathia, crumpled external ears |
1.1 Osteogenesis Imperfecta (OI)¶
OI is a collagen-related disorder characterized by brittle bones, fractures, and variable skeletal deformities. It is classified into 13 types based on genetic mutations and clinical features, with types I-IV being the most common.
1.2 Ehlers-Danlos Syndromes (EDS)¶
EDS is a group of hereditary connective tissue disorders characterized by joint hypermobility, skin hyperextensibility, and tissue fragility. Over 13 types exist, with hypermobile EDS (hEDS) being the most common.
1.3 Chondrodysplasias (CDs)¶
CDs are skeletal dysplasias caused by mutations in collagen or proteoglycan genes, leading to disproportionate short stature, joint abnormalities, and cartilage defects. Achondroplasia is the most common form.
1.4 Heritable Thoracic Aortic Aneurysm Disease (HTAD)¶
HTAD includes syndromic forms like Marfan syndrome (MFS) and Loeys-Dietz syndrome (LDS), which are linked to defects in TGF- β signaling and extracellular matrix proteins.
2. EPIDEMIOLOGY¶
OI has an estimated incidence of 1 in 10,000–15,000 births, with recessive forms more common in populations with high consanguinity. EDS has an incidence of ~1 in 5000 individuals for all forms, with hypermobile EDS being more common in females. Chondrodysplasias range from 1 in 2500 to 1 in 4000 births, with achondroplasia being the most common (1 in 26,000–28,000 live births). HTAD includes MFS (~1 in 3000–5000 births) and LDS (less common).
2.1 Osteogenesis Imperfecta¶
Type I OI is the most common, with an incidence of ~1 in 20,000. Types II and III are more severe, with Type II often lethal in utero. Recessive forms (Types VII–XXII) have higher incidence in consanguineous populations.
2.2 Ehlers-Danlos Syndromes¶
Hypermobile EDS is the most common, with a female predominance. Classic and vascular EDS are the most genetically elucidated, with incidences of 1 in 20,000 and 1 in 50,000–200,000, respectively.
2.3 Chondrodysplasias¶
Achondroplasia is the most common CD, with an incidence of 1 in 26,000–28,000 live births. Other forms like Stickler syndrome and Kniest syndrome have lower incidences.
2.4 Heritable Thoracic Aortic Aneurysm Disease¶
MFS has an incidence of ~1 in 3000–5000 births. LDS is less common, with exact incidence unknown. HTAD is often diagnosed in adulthood due to progressive aortic dilation.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
These disorders arise from mutations in genes encoding structural proteins like collagen, fibrillin, and proteoglycans. Defects in collagen synthesis, processing, or cross-linking lead to weakened connective tissue. TGF- β signaling defects in HTAD cause vascular and skeletal abnormalities. EDS involves mutations in collagen processing genes or extracellular matrix proteins.
3.1 Osteogenesis Imperfecta¶
Caused by mutations in COL1A1/COL1A2 (Types I-IV), SERPINF1 (Type V), or other collagen genes. Defects in collagen synthesis or processing lead to brittle bones and skeletal deformities.
3.2 Ehlers-Danlos Syndromes¶
Caused by mutations in COL3A1 (vascular EDS), COL5A1/COL5A2 (classic EDS), or other genes like ADAMTS2 (dermatosparaxis EDS). Defects in collagen assembly or processing lead to tissue fragility.
3.3 Chondrodysplasias¶
Caused by mutations in collagen (COL2A1, COL9A1-3) or proteoglycan genes (COMP, B3GALT7). Defects in cartilage development lead to skeletal dysplasia. Caused by mutations in FBN1 (MFS), TGFBR1/2 (LDS), or other genes. Defects in TGF- β signaling and extracellular matrix proteins lead to aortic dilation and connective tissue fragility.
4. CLINICAL FEATURES¶
Clinical manifestations vary by disorder but include skeletal abnormalities, joint hypermobility, skin fragility, and vascular complications. OI presents with fractures and deformities; EDS with joint laxity and skin hyperextensibility; CDs with disproportionate short stature; and HTAD with aortic dilation.
4.1 Osteogenesis Imperfecta¶
Bone fragility, fractures, blue sclerae, hearing loss, and dental abnormalities. Severe types may have respiratory compromise due to chest wall deformities.
4.2 Ehlers-Danlos Syndromes¶
Joint hypermobility, skin hyperextensibility, easy bruising, and vascular fragility. Vascular EDS may present with arterial ruptures or gastrointestinal bleeding.
4.3 Chondrodysplasias¶
Disproportionate short stature, joint abnormalities, and skeletal dysplasia. Achondroplasia presents with short limbs, lumbar lordosis, and respiratory issues.
4.4 Heritable Thoracic Aortic Aneurysm Disease¶
Aortic dilation, mitral valve prolapse, and risk of aortic dissection or rupture. LDS may also present with ocular findings like ectopia lentis.
5. DIFFERENTIAL DIAGNOSIS¶
Differential diagnoses include other connective tissue disorders, metabolic bone diseases, and genetic syndromes. For OI, differentiate from hypophosphatasia or osteomalacia. For EDS, consider other collagenopathies or vascular disorders. For HTAD, rule out aortic dissection or other vascular conditions.
5.1 Osteogenesis Imperfecta¶
Differentiate from hypophosphatasia (normal calcium/phosphate levels), osteogenesis imperfecta (collagen defects), or osteomalacia (low bone mineral density).
5.2 Ehlers-Danlos Syndromes¶
Distinguish from other collagen disorders like Marfan syndrome or vascular EDS. Genetic testing is critical for accurate diagnosis.
5.3 Chondrodysplasias¶
Differentiate from achondroplasia (distinct skeletal features) or other skeletal dysplasias like spondyloepiphyseal dysplasia.
5.4 Heritable Thoracic Aortic Aneurysm Disease¶
Distinguish from aortic dissection, Marfan syndrome, or other vascular disorders. Imaging and genetic testing are essential.
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnostic workup includes clinical evaluation, imaging (X-rays, MRI), genetic testing, and biochemical assays. Molecular testing is crucial for confirming genetic disorders.
Table 425-3: Classification of Ehlers-Danlos Syndromes¶
| TYPE | GENE | CLINICAL FEATURES | INHERITANCE |
|---|---|---|---|
| Classic EDS | COL5A1/COL5A2 | Joint hypermobility, skin hyperextensibility, easy bruising | Autosomal dominant |
| TYPE | GENE | CLINICAL FEATURES | INHERITANCE |
|---|---|---|---|
| Vascular EDS | COL3A1 | Arterial ruptures, gastrointestinal bleeding, skin fragility | Autosomal dominant |
| Hypermobile EDS | Unknown | Joint hypermobility, skin hyperextensibility, chronic musculoskeletal pain | Unknown |
| Kyphoscoliotic EDS | FKBP14 | Kyphoscoliosis, skin fragility, ocular abnormalities | Autosomal recessive |
| Dermatosparaxis EDS | ADAMTS2 | Severe skin fragility, joint laxity, muscle hypotonia | Autosomal recessive |
6.1 Osteogenesis Imperfecta¶
Genetic testing for COL1A1/COL1A2 mutations. Radiographic findings include osteopenia and characteristic bone deformities.
6.2 Ehlers-Danlos Syndromes¶
Genetic testing for COL3A1, COL5A1/COL5A2, or other EDS-associated genes. Slit-lamp examination for ocular findings.
6.3 Chondrodysplasias¶
Genetic testing for COL2A1, COMP, or other CD-related genes. Radiographic evaluation for skeletal abnormalities.
6.4 Heritable Thoracic Aortic Aneurysm Disease¶
Echocardiography for aortic dilation. Genetic testing for FBN1, TGFBR1/2, or other HTAD-associated genes.
7. MANAGEMENT & TREATMENT¶
Management is multidisciplinary, focusing on symptom relief, fracture prevention, and genetic counseling. Therapies include bisphosphonates, denosumab, and surgical interventions for severe cases.
Table 425-4: Heritable Thoracic Aortic Disease and Associated Genes and Proteins¶
| GENE | PROTEIN | CONDITION | OMIM | LOCUS |
|---|---|---|---|---|
| COL3A1 | a1(III) collagen chain | Vascular EDS | 130050 | 2q32 |
| FBN1 | Fibrillin 1 | Marfan syndrome | 154700 | 15q21.1 |
| MFAP5 | Microfibrillar associated protein 5 | Familial thoracic aortic aneurysm 9 | 616166 | 12p13.31 |
| LOX | Lysyl oxidase | Familial thoracic aortic aneurysm 10 | 617168 | 5q23.1 |
| TGFBR1 | Transforming growth factor receptor 1 | Loeys-Dietz syndrome 1 | 609192 | 9q22.33 |
| TGFBR2 | Transforming growth factor receptor 2 | Loeys-Dietz syndrome 2 | 610168 | 3p24.1 |
| GENE | PROTEIN | CONDITION | OMIM | LOCUS |
|---|---|---|---|---|
| SMAD3 | Mothers against decapentaplegic drosophila homolog 3 | Loeys-Dietz syndrome 3 | 613795 | 15q22.33 |
| TGFB2 | Transforming growth factor b2 | Loeys-Dietz syndrome 4 | 614816 | 1q41 |
| TGFB3 | Transforming growth factor b3 | Loeys-Dietz syndrome 5 | 615582 | 14q23.3 |
| SMAD2 | Mothers against decapentaplegic drosophila homolog 2 | Arterial aneurysms and dissections | / | 18q21.1 |
| ACTA2 | Smooth muscle actin a2 | Familial thoracic aortic aneurysm 6 | 611788 | 10q23.31 |
| MYH11 | Smooth muscle myosin heavy chain 11 | Familial thoracic aortic aneurysm 4 | 132900 | 16p13.11 |
| MYLK | Myosin light chain kinase | Familial thoracic aortic aneurysm 7 | 613780 | 3q21.1 |
| PRKG1 | Protein kinase cGMP-dependent type 1 | Familial thoracic aortic aneurysm 8 | 615436 | 10q11.2-q21.1 |
7.1 Osteogenesis Imperfecta¶
Bisphosphonates (e.g., zoledronic acid) for bone strengthening. Denosumab for severe cases. Orthopedic surgery for deformities. Physical therapy to improve mobility.
7.2 Ehlers-Danlos Syndromes¶
Physical therapy for joint stability. Avoidance of high-impact activities. Surgical correction of joint subluxations. Genetic counseling for family planning.
7.3 Chondrodysplasias¶
Symptomatic management of joint pain and deformities. Surgical correction of severe deformities. Genetic counseling for families.
7.4 Heritable Thoracic Aortic Aneurysm Disease¶
Regular aortic monitoring with imaging. Beta-blockers or ARBs to reduce aortic dilation. Surgical repair for aneurysms. Genetic counseling for family screening.
8. PROGNOSIS & COMPLICATIONS¶
Prognosis varies by disorder. OI can lead to respiratory failure, hearing loss, or cardiac complications. EDS may result in joint instability or vascular rupture. CDs can cause degenerative arthritis. HTAD is associated with aortic dissection or rupture, with high mortality in untreated cases.
8.1 Osteogenesis Imperfecta¶
Mild types have a normal life expectancy, while severe types may result in early mortality due to respiratory or cardiac complications.
8.2 Ehlers-Danlos Syndromes¶
Complications include joint dislocations, chronic pain, and vascular ruptures. Vascular EDS has a higher mortality rate due to aortic complications.
8.3 Chondrodysplasias¶
Long-term complications include degenerative arthritis and respiratory issues in severe cases.
8.4 Heritable Thoracic Aortic Aneurysm Disease¶
Untreated aortic dilation leads to dissection or rupture, with high mortality. Early intervention improves prognosis.
9. SPECIAL CONSIDERATIONS¶
Pregnancy management in OI requires careful monitoring due to increased fracture risk. Pediatric patients may need growth hormone therapy. Genetic counseling is essential for family planning. In HTAD, beta-blockers or ARBs are used to manage aortic dilation.
9.1 Pregnancy and OI¶
Pregnant women with OI are at risk for fractures and should avoid physical strain. Bisphosphonates may be used cautiously.
9.2 Pediatric Management¶
Growth hormone therapy for dominant OI. Physical therapy to prevent deformities. Nutritional support for bone health.
9.3 Genetic Counseling¶
Counseling for families to understand inheritance patterns and recurrence risks. Prenatal testing for at-risk pregnancies.
9,4 HTAD Management¶
Avoidance of physical stress. Beta-blockers or ARBs to reduce aortic dilation. Surgical repair for aneurysms.
10. KEY POINTS & CLINICAL PEARLS¶
- OI is caused by collagen defects, with types I-IV being the most common. 2. EDS is a group of disorders with over 13 types, with hypermobile EDS being the most common. 3. CDs are skeletal dysplasias caused by collagen or proteoglycan mutations. 4. HTAD includes syndromic forms like MFS and LDS, often linked to TGF- β signaling defects. 5. Genetic testing is critical for accurate diagnosis and family screening. 6. Management is multidisciplinary, with targeted therapies like bisphosphonates, denosumab, and vosoritide showing promise. 7. Early intervention improves outcomes in all these disorders.